Search
Login
My Portfolios Login
TradeMachine® Login
CML Research Pro Login
Get TradeMachine®
Get CML Research
Compare Products
Home
My Portfolios
CMLViz News
Breaking
Stock
Scanner
Tear Sheet
News
Profile
Stats
Stock Chart
Pivot Points
Financial Charts
Holders
Analysts
Day Trader
Back-Tester
SPX
3,910.47
+3.91
(
+0.10%
)
Dow 30
+0.15%
QQQ
+0.05%
VIX
27.77
+0.54
(
+1.98%
)
Y-Mabs Therapeutics Inc
NASDAQ:YMAB 10:59:00 AM EDT
14.61
-0.20
(
-1.35%
)
Products
Y-mAbs Announces FDA Acceptance Of Biologics License Application For Omblastys® For The Treatment Of Neuroblastoma For Priority Review
Published: 05/31/2022 13:34 GMT
YMAB
Y-Mabs Therapeutics Inc (
YMAB
)
- Y-mabs Announces FDA Acceptance of Biologics License Application for Omblastys® (omburtamab) for the Treatment of Neuroblastoma for Priority Review.
